These findings unveil a novel role for FPR2 in mediating LC3‐associated efferocytosis to alleviate colonic inflammation and suggest the therapeutic potential of COL as a biased agonist of FPR2 for colitis treatment. Here, MAP1LC3A is linked to colitis.